Find a Product

Kinase Targets By Therapeutic/Disease Area

DiscoverX offers the the largest commercial portfolio of kinase assay solutions for multiple therapeutic and disease areas.  Use the links below to browse our kinase portfolio by therapeutic area. Select targets shown - view more Kinase targets.


AAK1 ABL1 ABL1(E255K)-phosphorylated ABL1(F317I)-nonphosphorylated ABL1(F317I)-phosphorylated
ABL1(F317L)-nonphosphorylated ABL1(F317L)-phosphorylated ABL1(H396P)-nonphosphorylated ABL1(H396P)-phosphorylated ABL1(M351T)-phosphorylated
ABL1(Q252H)-nonphosphorylated ABL1(Q252H)-phosphorylated ABL1(T315I)-nonphosphorylated ABL1(T315I)-phosphorylated ABL1(Y253F)-phosphorylated
ABL1-nonphosphorylated ABL1-phosphorylated ABL2 ACVR1 ACVR1B
ACVR1B/BMPR2 ACVR1C/ACVR2 ACVR1C/ACVR2B ACVR2/ACVR1 ACVR2A
ACVR2B ACVRL1 ACVRL1/ACVR2 ACVRL1/ACVR2B ACVRL1/BMPR2
ADCK3 ADCK4 AKT1 AKT2 AKT3
ALK ALK(1151Tins) ALK(C1156Y) ALK(F1174L) ALK(L1196M)
AMPK-alpha1 AMPK-alpha2 ANKK1 ARK5 ASK1
ASK2 AURKA AURKB AURKC AXL
BIKE BLK BMPR1A BMPR1A/ACVR2 BMPR1A/ACVR2B
BMPR1A/BMPR2 BMPR1B BMPR1B/ACVR2 BMPR1B/ACVR2B BMPR1B/BMPR2
BMPR2 BMX BRAF BRAF(V600E) BRK
BRSK1 BRSK2 BTK BUB1 CAMK1
CAMK1B CAMK1D CAMK1G CAMK2A CAMK2B
CAMK2D CAMK2G CAMK4 CAMKK1 CAMKK2
CASK CDC2L1 CDC2L2 CDC2L5 CDK1
CDK10 CDK11 CDK12 CDK2 CDK20
CDK3 CDK4 CDK4-cyclinD1 CDK4-cyclinD1(F93L) CDK4-cyclinD3
CDK5 CDK6 CDK7 CDK8 CDK9
CDKL1 CDKL2 CDKL3 CDKL5 CHEK1
CHEK2 cINSRa cINSRb CIT c-KIT
CLK1 CLK2 CLK3 CLK4 c-MET/c-MET
c-Ret-GFRα1 c-Ret-GFRα2 CSF1R CSF1R/CSF1R CSF1R-autoinhibited
CSF3R-JAK1 CSK CSNK1A1 CSNK1A1L CSNK1D
CSNK1E CSNK1G1 CSNK1G2 CSNK1G3 CSNK2A1
CSNK2A2 CTK DAPK1 DAPK2 DAPK3
DCAMKL1 DCAMKL2 DCAMKL3 DDR1 DDR2(T654M)
DLK DMPK DMPK2 DRAK1 DRAK2
DYRK1A DYRK1B DYRK2 EGFR EGFR(E746-A750del)
EGFR(G719C) EGFR(G719S) EGFR(L747-E749del, A750P) EGFR(L747-S752del, P753S) EGFR(L747-T751del,Sins)
EGFR(L858R) EGFR(L858R,T790M) EGFR(L861Q) EGFR(S752-I759del) EGFR(T790M)
EGFR/EGFR EGFR/ErbB2 EIF2AK1 EPHA1 EPHA2
EPHA3 EphA4 EphA5 EPHA6 EphA7
EPHA8 EphB1 EphB2 EphB3 EphB4
EPHB6 ErbB1 ERBB2 ErbB2/ErbB3 ErbB2/ErbB4
ErbB2-ErbB3 ERBB3 ErbB4 ErbB4/ErbB4 ERK1
ERK1(Q122L) ERK2 ERK3 ERK4 ERK5
ERK8 ERN1 FAK FER FES
FGFR1 FGFR1-α-Klotho FGFR1-β-Klotho FGFR2 FGFR2(N550K)
FGFR3 FGFR3(G380R)/FGFR3(G380R) FGFR3(G697C) FGFR3(K650E) FGFR3(V555M)
FGFR3/FGFR3 FGFR4 FGFR4 FGFR4-α-Klotho FGFR4-β-Klotho
FGR FLT1 FLT3 FLT3(D835H) FLT3(D835V)
FLT3(D835Y) FLT3(ITD) FLT3(ITD,D835V) FLT3(ITD,F691L) FLT3(K663Q)
FLT3(N841I) FLT3(R834Q) FLT3-autoinhibited FLT4 FRK
FYN GAK GCN2(Kin.Dom.2,S808G) GHR-JAK1 GHR-JAK2
GRK1 GRK2 GRK3 GRK4 GRK7
GSK3A GSK3B HASPIN HCK HIPK1
HIPK2 HIPK3 HIPK4 HPK1 HUNK
ICK IGF1R IKK-alpha IKK-beta IKK-epsilon
INSR INSRa INSRb INSRR IRAK1
IRAK2 IRAK3 IRAK4 ITK JAK1(JH1domain-catalytic)
JAK1(JH2domain-pseudokinase) JAK2(JH1domain-catalytic) JAK3 JAK3(JH1domain-catalytic) JNK1
JNK2 JNK3 KDR KDR/KDR KIT
KIT(A829P) KIT(D816H) KIT(D816V) KIT(L576P) KIT(V559D)
KIT(V559D,T670I) KIT(V559D,V654A) KIT-autoinhibited LATS1 LATS2
LCK LIMK1 LIMK2 LKB1 LOK
LRRK2 LRRK2(G2019S) LTK LYN LZK
MAK MAP3K1 MAP3K15 MAP3K2 MAP3K3
MAP3K4 MAP4K2 MAP4K3 MAP4K4 MAP4K5
MAPKAPK2 MAPKAPK5 MARK1 MARK2 MARK3
MARK4 MAST1 MEK1 MEK2 MEK3
MEK4 MEK5 MEK6 MELK MERTK
MET MET(M1250T) MET(Y1235D) MINK mINSRa
mINSRb MKK7 MKNK1 MKNK2 MLCK
MLK1 MLK2 MLK3 MLKL MLKL(full-length)
MRCKA MRCKB MST1 MST1R MST2
MST3 MST4 MTOR MUSK MYLK
MYLK2 MYLK4 MYO3A MYO3B NDR1
NDR2 NEK1 NEK10 NEK11 NEK2
NEK3 NEK4 NEK5 NEK6 NEK7
NEK9 NIM1 NLK OSR1 p38-alpha
p38-beta p38-delta p38-gamma PAK1 PAK2
PAK3 PAK4 PAK6 PAK7 PASK
PCTK1 PCTK2 PCTK3 PDGFRa PDGFRb
PDPK1 PFCDPK1(P.falciparum) PFPK5(P.falciparum) PFTAIRE2 PFTK1
PHKG1 PHKG2 PI3Kδ PIK3C2B PIK3C2G
PIK3CA PIK3CA(C420R) PIK3CA(E542K) PIK3CA(E545A) PIK3CA(E545K)
PIK3CA(H1047L) PIK3CA(H1047Y) PIK3CA(I800L) PIK3CA(M1043I) PIK3CA(Q546K)
PIK3CB PIK3CD PIK3CG PIK4CB PIKFYVE
PIM1 PIM2 PIM3 PIP5K1A PIP5K1C
PIP5K2B PIP5K2C PKAC-alpha PKAC-alpha(L206R) PKAC-beta
PKMYT1 PKN1 PKN2 PKNB(M.tuberculosis) PLK1
PLK2 PLK3 PLK4 PRKCD PRKCE
PRKCH PRKCI PRKCQ PRKD1 PRKD2
PRKD3 PRKG1 PRKG2 PRKR PRKX
PRLR-JAK1 PRLR-JAK2 PRP4 PYK2 QSK
RAF1 RET RET(A883F) RET(M918T) RET(V804E)
RET(V804L) RET(V804M) rhTrkA-rhP75 RIOK1 RIOK2
RIOK3 RIPK1 RIPK1 RIPK2 RIPK3
RIPK3 RIPK4 RIPK5 ROCK1 ROCK2
ROS1 RPS6KA4(Kin.Dom.1-N-terminal) RPS6KA4(Kin.Dom.2-C-terminal) RPS6KA5(Kin.Dom.1-N-terminal) RPS6KA5(Kin.Dom.2-C-terminal)
RSK1(Kin.Dom.1-N-terminal) RSK1(Kin.Dom.2-C-terminal) RSK2(Kin.Dom.1-N-terminal) RSK2(Kin.Dom.2-C-terminal) RSK3(Kin.Dom.1-N-terminal)
RSK3(Kin.Dom.2-C-terminal) RSK4(Kin.Dom.1-N-terminal) RSK4(Kin.Dom.2-C-terminal) rTrkA-rP75 S6K1
SBK1 SGK SgK110 SGK2 SGK3
SIK SIK1 SIK2 SLK SNARK
SNRK SRC SRMS SRPK1 SRPK2
SRPK3 STK16 STK33 STK35 STK36
STK39 SYK TAK1 TAOK1 TAOK2
TAOK3 TBK1 TEC TESK1 TGFBR1
TGFBR1/ACVR2 TGFBR1/ACVR2B TGFBR1/TGFBR2 TGFBR2 TIE1
TIE2 Tie2 TLK1 TLK2 TNIK
TNK1 TNK2 TNNI3K TrkA TrkA-P75
TrkB TrkB-P75 TrkC TrkC-P75 TRPM6
TSSK1B TSSK3 TTK TXK TYK2
TYK2(JH1domain-catalytic) TYK2(JH2domain-pseudokinase) TYRO3 ULK1 ULK2
ULK3 VEGFR2 VPS34 VRK2 WEE1
WEE2 WNK1 WNK2 WNK3 WNK4
YANK1 YANK2 YANK3 YES YES1
YSK1 YSK4 ZAK ZAP70

Cancer Research

Epigenetic, Kinase, Pathway, GPCR and NHR Functional Cellular Assays for Novel Therapeutic Discovery
Development of both small and large molecule inhibitors that target cellular signaling modalities involved in tumor growth, angiogenesis, cancer progression and metastasis are inherent in anticancer treatments, resulting in novel therapeutic approaches for cancer prevention and treatment.

+

CNS Research

Epigenetic, Kinase, Pathway, GPCR and NHR Functional Cellular Assays for Novel Therapeutic Discovery
The rapid expansion of CNS drug discovery efforts is associated with an increase in neurological and psychiatric conditions in the growing geriatric population. While small molecules targeting extracellular receptors represent more than 80% of commercially available CNS-related drugs, considerable advancements have also been made in the development of antibodies, vaccines, aptamers, small interfering RNA, and other biologics for the treatment of Alzheimers, Parkinson’s, Multiple Sclerosis and other CNS disorders.

+

Inflammation Research

Epigenetic, Kinase, Pathway, GPCR and NHR Functional Cellular Assays for Novel Therapeutic Discovery
Inflammatory diseases are slow to onset and chronic in nature and can lead to a host of debilitating diseases, such as rheumatoid arthritis, inflammatory bowel disease, Crohn’s disease, psoriasis, atherosclerosis and even cancer. As the molecular mechanisms that regulate functional inflammatory responses are now better understood, drug discovery programs are focused on developing highly efficacious anti-inflammatory therapeutics that show the least amount of side effects over prolonged treatment periods.

+

Metabolic Research

GPCR, Kinase, Pathway, NHR and Protease Functional Cellular Assays for Novel Therapeutic Discovery
The increased prevalence of obesity, Type II diabetes and associated complications has become an alarming global health problem. G-Protein Coupled Receptors (GPCRs), Kinases, Nuclear Hormone Receptors (NHRs) and Proteases are important therapeutic drug targets for metabolic research as these receptors play a pivotal role in the regulation of insulin and glucagon secretion. Therefore, novel pharmacologic approaches are required to develop fast acting and efficacious compounds that can modulate the ways in which the body controls metabolism, weight gain and body composition.

+

Cardiovascular Research

GPCR, Kinase, Pathway, NHR and Protease Functional Cellular Assays for Novel Therapeutic Discovery
Cardiovascular diseases (CVDs) are the number one cause of death worldwide, with more people dying each year from CVDs than from any other cause, including cancer. Because a wide variety of conditions can lead to heart disease including atherosclerosis, heart infections and structural or congenital defects, cardiovascular drug development programs are often quite complex and require multidisciplinary approaches. Now more than ever, novel pharmacological strategies that target specific receptors or proteins of interest involved in CVDs are required for the safe and effective treatment and prevention of cardiovascular disease.

+

Respiratory Research

GPCR, Kinase, Pathway, NHR and Protease Functional Cellular Assays for Novel Therapeutic Discovery
Chronic respiratory diseases that arise from infectious agents, environmental pollutants, smoking or allergic reactions represent a major public health challenge in both industrialized and developing countries. Although several blockbuster drugs already exist that ease symptoms and improve the quality of life in patients suffering from these diseases, drug discovery programs continue to focus on the development of small molecules and other biologics against therapeutic targets for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and lung cancer.

+

Pain and Addiction Research

GPCR, Kinase, Pathway and NHR Functional Cellular Assays for Novel Therapeutic Discovery
The combination of chronic pain and addiction is a complex, debilitating medical disorder that is extremely difficult to treat due to the high likelihood of opioid dependence. Recent advances in chronic pain research have uncovered the biological complexity of the disorder and led to the development of next generation non-steroidal anti-inflammatory drugs, antidepressants and anticonvulsant drugs to mitigate chronic pain. Researchers are now focused on developing small molecule and other biologics to target widely expressed pain receptors aimed at not only alleviating pain but also lessening abuse potential of opiod drugs.

+

Digestive and Renal Research

GPCR, Kinase, Pathway and NHR Functional Cellular Assays for Novel Therapeutic Discovery
Genetic and environmental factors that disrupt homeostatic digestive and renal processes can result in chronic kidney disease and/or kidney failure, glomerulonephritis, Celiac & Crohn’s diseases and more. G-Protein Coupled Receptors (GPCRs), Kinases and Nuclear Hormone Receptors (NHRs) expressed in renal and digestive tissues represent the most tractable targets for development of small and large molecule drugs that alleviate and prevent urological and metabolic abnormalities.

+

Reproductive Research

GPCR, Kinase and NHR Functional Cellular Assays for Novel Therapeutic Discovery
The reproductive system coordinates signaling pathways in many different cell types which leads to oogenesis and spermatogenesis, ovulation, implantation, menstruation and ultimately childbirth. Precise control of this cellular communication and signaling is critical for normal development and fertility in humans. G-Protein Coupled Receptors (GPCRs), Kinases and Nuclear Hormone Receptors (NHRs) are important therapeutic targets for reproductive drug discovery as these receptors play key physiological roles and their dysfunction underlies many pathological conditions related to infertility and disease.

+

Dermatology Research

GPCR, Kinase, Pathway and NHR Functional Cellular Assays for Novel Therapeutic Discovery
Skin is the largest organ in the body, susceptible to environmental stresses that can lead to early onset of aging and other conditions such as dermatitis, eczema, psoriasis, rosacea, alopecia, and even cancer. As the role of the skin (dermis) in whole body wellness becomes better defined, interest has grown in developing safe and efficacious therapeutics that combat disease processes and/or reverse age related ailments without the need for more invasive surgical treatment.

+

Post-Traumatic Stress Disorder Research

GPCR, Kinase, Pathway and NHR Functional Cellular Assays for Novel Therapeutic Discovery
Post-Traumatic Stress Disorder Research (PTSD) is a severe anxiety disorder that develops following a psychologically traumatizing event. Largely ineffective antidepressants and anti-anxiety medications target glucocorticoid pathway, but do not treat the disorder. Researchers have studied genes encoding brain’s fear circuits, especially focusing on GPCRs, Kinases and NHRs as important therapeutic signaling modalities that regulate responses to fear and stress. For example, researchers have recently uncovered specific neurobiological differences including lower levels of Serotonin 1B in the brains of people who have PTSD and those who do not.

+

Ocular Research

GPCR, Kinase and Pathway Functional Cellular Assays for Novel Therapeutic Discovery
Eye-related pathologies such as inflammation, agerelated macular degeneration (AMD), diabetic retinopathy, cataracts or glaucoma affect millions of people worldwide and can result in long term vision loss. G-Protein Coupled Receptors (GPCRs), Kinases and Pathways have emerged as important therapeutic targets for ophthalmology drug discovery as these receptors are expressed in the eye and have a wide range of physiological functions.

+

Auditory and Otology Research

GPCR, Kinase, Pathway and NHR Functional Cellular Assays for Novel Therapeutic Discovery
Recent advances in auditory and otological research have led to a greater understanding of the molecular and physiologic basis for hearing loss. This has enabled novel discoveries in the area of ototoxicity as well as prospected the development of new and improved therapeutic options for patients in the treatment of ear disorders. G-protein Coupled Receptors (GPCRs), Kinases and Nuclear Hormone Receptors (NHRs) are widely expressed in the sensory system and targeted for development of safe and efficacious therapies to prevent degenerative hearing loss, inner ear disease, and long term damage from noise and our environment.

+